A case report of severe hyponatremia secondary to Paxlovid-induced SIADH

Authors

Sarah Mohamed, School of Medicine Cairo University Giza Egypt.
Mostafa Reda Mostafa, Rochester Regional HealthFollow
Mohamed Magdi Eid, Rochester Regional HealthFollow
Yossef Hassan AbdelQadir, Faculty of Medicine Alexandria University Alexandria Egypt.
Yomna Ali Abdelghafar, Faculty of Medicine Alexandria University Alexandria Egypt.
Sarya Swed, Faculty of Medicine Aleppo University Aleppo Syria.
Bishara Jahshan, Rochester Regional HealthFollow
Waddah Abd El-Radi, Rochester Regional HealthFollow

Department

Medicine

Document Type

Article

Publication Title

Clinical Case Reports

Abstract

Nirmatrelvir-ritonavir (Paxlovid) is a brand-new oral antiviral medication for treating mild to severe COVID-19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir-nirmatrelvir on December 22, 2021, to treat COVID-19. We describe a case of mild COVID-19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study.

First Page

e7860

DOI

10.1002/ccr3.7860

Volume

11

Issue

9

Publication Date

9-1-2023

PubMed ID

37655131

Recommended Citation

Mohamed, S., Reda Mostafa, M., Eid, M. M., AbdelQadir, Y. H., Abdelghafar, Y. A., Swed, S., Jahshan, B., & Abd El-Radi, W. (2023). A case report of severe hyponatremia secondary to Paxlovid-induced SIADH. Clinical Case Reports, 11 (9), e7860. https://doi.org/10.1002/ccr3.7860